Oncology technology developer Novocure is touting a new study involving its Tumor Treating Fields electromagnetic field therapy published online April 23 in the International Journal of Radiation Oncology, Biology, Physics.
The post-hoc analysis of Novocure's EF-14 clinical trial showed that higher doses of Tumor Treating Fields improved survival in patients newly diagnosed with glioblastoma and marks the first reported analysis demonstrating patient-level dose responses to the technology, according to the vendor. The study provides a definition for Tumor Treating Fields dose and creates a dosimetry and treatment planning framework, noted lead study author Dr. Matthew Ballo of the West Cancer Center & Research Institute in Germantown, TN.
